Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest vemurafenib Stories

2014-03-26 12:26:20

The Highest Percentage of Non-Prescribers Anticipate Prescribing Tafinlar and Mekinist Within the Next One to Three Months, According to Findings from Decision Resources Group BURLINGTON, Mass., March 26, 2014 /PRNewswire/ -- Decision Resources Group finds that at six months post-launch in the United States, 45 percent of surveyed U.S. medical oncologists have prescribed GlaxoSmithKline's BRAF inhibitor Tafinlar for BRAF-mutation-positive unresectable or metastatic melanoma compared with 28...

2014-01-16 14:22:49

University of Leicester researchers deploy 'precision medicine' to successfully target advanced form of leukaemia with skin cancer drug A team of scientists from the University of Leicester has demonstrated a novel treatment for Hairy Cell Leukaemia (HCL), a rare type of blood cancer, using a drug administered to combat skin cancer. The research, which is published today (Thursday 16 January) in the New England Journal of Medicine, indicates Vemurafenib, a BRAF inhibitor that has been...

Newly Discovered Molecular Targets May Treat Difficult Melanomas
2014-01-01 08:56:37

redOrbit Staff & Wire Reports - Your Universe Online A recently-published study in the journal Clinical Cancer Research supported by the Stand Up To Cancer (SU2C) charitable foundation has identified new molecular targets which could potentially result in new remedies for difficult-to-treat melanomas. A team of investigators, including Dr. Jeffrey A. Sosman of the Vanderbilt-Ingram Cancer Center and Dr. William Pao of the Vanderbilt University School of Medicine, found two novel...

2013-12-02 08:31:59

Surveyed Oncologists Report that Yervoy Holds Most Second-Line Patient Share in the BRAF-Mutation-Positive Population, According to a New Report from BioTrends Research Group EXTON, Pa., Dec. 2, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, according to oncologists surveyed in Q3 2013, Roche/Genentech/Daiichi Sankyo/Chugai's Zelboraf, on average, garners 50 percent patient...

2013-11-26 08:28:16

Surveyed Oncologists Indicate that Yervoy Holds the Most Patient Share in the First-Line BRAF Wild-Type Population, According to a New Report from BioTrends Research Group EXTON, Pa., Nov. 26, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, according to oncologists surveyed in Q3 2013, Roche/Genentech/Daiichi Sankyo/Chugai's Zelboraf is the patient share leader in the...

Study Finds Drug-Resistant Melanoma Treatments May Be Enhanced
2013-11-22 09:27:11

April Flowers for redOrbit.com - Your Universe Online More than 8,000 Americans are killed each year by melanoma -- the deadliest form of skin cancer. The presence of mutations in a gene known as the BRAF gene drives approximately 40 percent of advanced melanoma tumors. New medications, called BRAF inhibitors, have shown an ability to rapidly shrink melanoma tumors, however BRAF-mutated tumors often resist early treatment and only partially respond to BRAF inhibitors, which leaves...

2013-10-31 08:32:38

ARRY-520 Multiple Myeloma Registration Study Expected in 2014 BOULDER, Colo., Oct. 31, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the first quarter of its fiscal year ending June 30, 2014. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Revenue for the first quarter of fiscal 2014 was $14.2 million, compared to $15.8 million for the same period in fiscal 2013. The cost of partnered programs increased to $10.7 million,...

2013-10-22 12:25:09

More Than Three-Quarters of Non-Prescribers Anticipate Prescribing Tafinlar and Mekinist Within the Next Six Months, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 22, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that at one month post-launch, approximately one-quarter of surveyed U.S. medical oncologists have prescribed GlaxoSmithKline's BRAF-inhibitor...

2013-10-01 12:31:10

Exclusive license agreement paves the way for industry's first BRAF V600E IHC test TUCSON, Ariz., Oct 1, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced the global launch of the industry's first BRAF V600E immunohistochemistry (IHC) test(1) to detect the BRAF V600E mutation in a variety of tumors. The test is designed to detect the most frequent BRAF mutation, V600E, which has been found to play a key role in a variety of...

2013-10-01 04:22:39

Cell-free DNA assay transferred to CLIA laboratory for patient testing SAN DIEGO, Oct. 1, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced availability of the first urine test for cancer mutation monitoring through the company's CLIA laboratory. The robustness of Trovagene's ultra-sensitive assay procedure has been demonstrated for detection of the BRAF V600E mutation from cell-free DNA in urine. This mutation...